MannKind (MNKD) Chief Medical Officer Blank to step down

MannKind (NASDAQ: MNKD) disclosed that on May 9, 2025, the company and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company. On May 14, 2025, the Company and Mr. Blank entered into a transition and separation agreement (the “Agreement”) regarding the terms of Mr. Blank’s transition and separation from the Company. Pursuant to the Agreement, effective May 14, 2025, Mr. Blank became a non-executive employee of the Company, reporting to the Company’s Chief Executive Officer, and the parties agreed that Mr. Blank’s last day of employment with the Company will be August 1, 2025 (the “Separation Date”). In addition, subject to Mr. Blank providing the Company with effective releases and waivers of claims when required under the Agreement, Mr. Blank will be entitled to receive (i) continuation of his base salary for 13 weeks following the Separation Date, until October 31, 2025, (ii) a one-time special bonus of $386,000, payable in January 2026, and (iii) reimbursement for COBRA premiums following the Separation Date until October 31, 2025. Mr. Blank’s equity awards will continue to be eligible for vesting while he remains employed with the Company.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• PPG names three segment leaders effective September 2026
• Palo Alto Networks launches critical infrastructure AI defense program